DiabetesSource

In a year that will be remembered for swine flu and health care reform, the American Diabetes Association today released a year-in-review list on another topic that received major headlines in 2009: diabetes. The list, found at diabetes.org, focuses on achievements made in 2009 to stop diabetes.

One of the top global pharmaceutical companies has initiated an observational study on the prevalence of Diabetes and Hypertension called SITE (Screening India's Twin Epidemics) in collaboration with Max Neeman International, an India based Contract Research Organization specializing in Phase II-IV clinical trials for pharmaceutical, biotechnology, device and nutraceutical companies. The study surveying both the ailments has been initiated for the first time in India. It will focus on the prevalence of the twin epidemic in India (Diabetes & Hypertension). This observational study is currently being conducted in six regions encompassing 12000 patients cumulatively (2000 patients per region). Site management and data analysis for all the regions is being managed by Max Neeman International.

Riverside Medical Center, one of the leading hospitals in Chicago area, unveils its Sweet Solution program this month. This diabetes prevention program will help men, women and children all over the Chicago hospital area prevent diabetes and lead healthier lifestyles.

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that over 70 percent of surveyed U.S. physicians indicate there is a high need for diabetes drugs with novel mechanisms of action versus 15 percent who say there is a high need for additional DPP-IV inhibitors. Both surveyed physicians and patients favor agents with excellent glucose lowering ability and physicians in particular say the most influential attribute would be if an agent could reduce HbA1c levels by two percent.